Sector Expert: Ling Wang

Chardan Capital Markets

Ling Wang, CFA, was previously a senior vice president and senior biotechnology analyst at Brean Murray, Carret & Co. Prior to her work at Brean Murray, she was a research associate covering biotechnology stocks at Rodman & Renshaw from 2006 to 2008. From 2004 to 2006 she was a research assistant in the life science group at Manning & Napier Advisors, Inc., an investment firm with approximately $16 billion in assets under management. Wang earned her undergraduate degree in biology from Beijing University. She also holds a master's degree in molecular pharmacology from Albert Einstein College of Medicine and an Master's of Business Administration degree in finance from Yale University.



Recent Quotes

"IMNP's first-class bertilimumab has great potential to offer therapy for large, unmet medical needs."

— Ling Wang, Chardan Capital Markets (5/14/14)
more >

"STEM's shares are significantly undervalued."

— Ling Wang, Chardan Capital Markets (1/10/14)
more >



Due to permission requirements, not all quotes are shown.